Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund, of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each at 5.5 pence per Ordinary Share.
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”).
Proteome Sciences is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company’s interim results statement of 14 September 2016.
Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.
Proteome Sciences partners with the BioCapture Network in this interdisciplinary project we will design high affinity responsive molecular capture materials targeting tumor specific markers. Molecularly imprinted polymers or “plastic antibodies” and other smart materials will be developed and used to detect and sense previously inaccessible tumor markers or to discover novel disease biomarkers.
Notice of a General Meeting of Proteome Sciences Plc, to be held at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ at 10 a.m. on 29 November 2016.
genomeweb.com-"The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease."
“This study clearly demonstrates the potential of combined tissue and fluid proteomics to discover and validate low abundant, tissue-derived biomarkers in peripheral fluids, which in this case resulted in the widest coverage of both tau and phosphorylated tau in human cerebrospinal fluid.
We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.